Sergio A. Email & Phone Number

New York, Ny, Us

Tarrytown, New York, Us

• Selected to join project and lead key workstreams for Regeneron's International Expansion of Oncology Business Unit. Worked with global strategy consultancies to define international footprint strategy, and program/project management across Commercial area workstreams.• Led development of business case for Japan market entry, followed by positive regulatory action, and favorable business outcomes in Y1 post-launch(Mar 2023)• Led commercial area for selection of local Distribution Partners in Asia Pacific, Latin America and Central & Eastern European regions• Led Commercial Hub development and presented Hub Strategy to C-Suite decision makers advancing plans for small to mid-sized European markets.• Engaged existing partner colleagues across markets to define operational and executional transition efforts for Commercial Hub including.

Tarrytown, New York, Us

• Managed governance process for US Oncology Business Unit Leadership Team: Planning cyclesbusiness performance management, KPI assessment, corporate strategy alignment, alliance management meetings, general administration, and other areas while representing the Oncology Leadership Team• Led project to assess Key Accounts Capabilities including performance and company presence at leading institutions. Worked with ZS Associates to define strategy and structure for development of Oncology Key Accounts Leader function an important element of the Business Unit operating model.• Led US Commercial Alliance Transition effort to support acquisition of full product rights for LIBTAYO from alliance partner. Drove clarity and alignment across core workstreams, managed risk mitigation to ensure business continuity.• Partnered with HR & OD leaders on Ways of Working initiatives leveraging opportunities to achieve Oncology Business Unit strategic objectives, while driving improved collaboration across the LT and the broader organization.

Rahway, New Jersey, Us

• Commercial Leader for Oncology Alliances with primary focus on Women’s Cancers including TNBC, Ovarian, Endometrial and Cervical Cancers.• Member of highly collaborative cross-functional team responsible for developing the Marketing Strategy and tools to inform strategic choices and Global Brand Plan for the TNBC new product launch.• Latin America Lead for portfolio expansion via strategic partnerships with AZ and Eisai. Led regional TNBC brand planning effort and execution.• Partnered with US Marketing Team on development of TNBC Strategy and Launch Readiness

Rahway, New Jersey, Us

• Responsible for executing strategic choices enabling KEYTRUDA to become the top selling biopharmaceutical brand in the history of Mexico’s Private Sector and the top Oncology brand in the highly fragmented complex Public Sector.• Led turn around and accelerated business unit growth from $18M +$45M USD driven by 1L NSCLC.• Provided leadership in cross-functional collaborative efforts and in building multiple capabilities including brand plan development, innovation strategic choice, opportunistic market events, and account planning, among others.• Established strong performance trend and ultimately 5Y Long Range Operating Plan to build-out +$150M annual sales business.• Led team to achieve top performance and market leadership in trade and government sectors, including significant improvements in Brand share (69% Trade) and Evolution Index: (122 vs. baseline 87 Trade EI).• Managed team of +45 FTEs across Marketing, Sales, Access, Commercial/ Government, Accounts, and Comm Ops.• Chartered initiative to build-out Oncology commercial capabilities.. Defined strategy and growth objectives, and deployed change in go-to-market model,, setting up business for longer-term growth across Mexico’s Federal Sector.• Sponsored pull-through activities that achieved unexpected +$2.2M additional Federal and decentralized Government Account purchases, despite significant barriers resulting from Federal Government admin turnover.• Drove additional growth +$4M anti-emetics business (EMEND, ONICIT) in Federal Sector Sales.• Led team in laser-focused execution and pull-through. Spillover impact led to Oct 2019 Evolution Index: 128 Month; 107 quarter.• Collaborated with members of MSD Mexico affiliate leadership team in key governance committees.

Rahway, New Jersey, Us

Rahway, New Jersey, Us

Rahway, New Jersey, Us

Rahway, New Jersey, Us

Rahway, New Jersey, Us

Rahway, New Jersey, Us

Mba, General Management: Finance-Marketing-Strategy-Biotech

Business Leadership Program - Biopharmaceuticals, Corporate Executive Education

B.S., Industrial/Organizational Psychology & Business Administration